Centre for Psychiatric Epidemiology and Psychopathology (CEPP)



The Centre for Psychiatric Epidemiology and Psychopathology (CEPP, formerly UREP [Research Unit for Psychiatric Epidemiology and Psychopathology]), created in 1994, is a multidisciplinary research unit including psychiatrists, psychologists, research fellows, epidemiologists, statisticians and data-managers. Activities of the CEPP combine research, teaching of psychiatric epidemiology and psychopathology, and consulting for clinical research of the department of psychiatry (logistic platform of clinical research, activities related to the Clinical Research Commission).

Research projects

The scientific goals of the CEPP are :

  • to study psychiatric disorders as well as comorbidity between these psychopathologies;
  • to identify risk factors associated with the pathogenesis of mood disorders;
  • to investigate the familial aggregation patterns of psychiatric disorders among probands and their first-degree relatives (parents, siblings, offspring);
  • to better understand the complex associations between cardiovascular disorders, cardiovascular risk factors and psychiatric disorders.

The CEPP was involved in the translation, adaptation and validation of instruments used to determine the phenotype of psychiatric disorders and environmental risk factors.

Various collaborations with other units and departments are ongoing. The two current major research projects are a prospective clinical cohort study (1) and a prospective population based cohort study (2).

Ongoing projects

  1. Clinical family study: Lausanne-Geneva Family and High Risk Study of Mood and Substance Use Disorders
    - NCCR Synapsy – Endophenotypes of mood disorders
  2. Population based cohort study: Colaus|PsyColaus

National and international collaborations

  • G. Waeber, P. Vollenweider, Department of Internal Medicine, CHUV;
  • V.Mooser, Department of Pathology and Laboratory Medicine, CHUV;
  • M. Bochud, P. Marques-Vidal, Institute of Social and Preventive Medicine, CHUV;
  • P. Conus, Service of General Psychiatry, Department of Psychiatry, CHUV;
  • K. Do Cuénod, Center for Psychiatric Neurosciences, CHUV;
  • C. Eap, Unit of Pharmacogenetics and Clinical Psychopharmacology, Centre for Psychiatric Neurosciences, CHUV;
  • A. von Gunten, J. Popp, Service of Old Age Psychiatry, Department of Psychiatry, CHUV;
  • F. Démonet, M. Knyazeva, Leenaards Memory Centre, Neurosciences, CHUV;
  • B. Draganski, Neurosciences, CHUV;
  • F. Paccaud, Community Health and Medicine, CHUV;
  • D. Hans, O. Lamy, Bone Disease Centre, CHUV;
  • M. Tafti, R. Heinzer, Sleep Research Unit, CHUV;
  • Z. Kutalik, Department of Medical Genetics, University of Lausanne; Swiss Institute of Bioinformatics, Lausanne;
  • P. Magistretti, P. Marquet, Laboratory of Neuroenergetics and Cellular Dynamics, Brain Mind Institute, EPFL;
  • J-M. Aubry, Neuroendocrinology, Psychopharmacology and Mood Disorders, Department of Psychiatry, HUG;
  • J-M. Gaspoz, Community Medecine and Primary Care, HUG;
  • V. Ajdadic-Gross, Social and General Psychiatry, University Hospital, Zurich;
  • C. Hock, L. Rajendran, Psychiatry Research and Psychogeriatric Medicine, Psychiatric University Hospital, Zurich;
  • T.F. Lüscher, Cardiology and Cardiovascular Research, University of Zurich;
  • O. Devuyst, Institute of Physiology, University of Zurich;
  • B. Hasse, P. Tarr, Swiss HIV cohort, University Hospital, Zurich;
  • R. von Känel, Psychosomatic Medicine, University Hospital, Bern;
  • N. Probst, Institute of Social and Preventive Medicine, University of Basel;
  • K. Merikangas, Genetic Epidemiology Research Branch, Intramural Research Program, National Institute of Mental Health, Bethesda, US;
  • D.M. Waterworth, GlaxoSmithKline, Philadelphia, US;
  • J. Hettema, Virginia Institute for Psychiatric and Behavioral Genetics, Richmond, US;
  • C. Kühner, Central Institute for Mental Health, Mannheim, DE;
  • N. Wareham, Epidemiology Unit, University of Cambridge, UK;
  • T. Frayling, Pesinsula Medical School, Exeter, UK;
  • J. Kooner, National Heart and Lung Institute, Imperial College London, UK;
  • I. Barroso, Wellcome Trust Sanger Institute, UK;
  • P. McGuffin, King’s College, London, UK;
  • S. Libert, L. Guarente, Massachusetts Institute of Technology, Cambridge, UK;
  • I. Skoog, Center of Neuropsychiatric Epidemiology, Gothenburg, SE;
  • F. Tozzi, Clinical Sciences-Aptuit Medecine Research Centre, Verona, IT;
  • A. Ramfos, C. Georgousopoulos, P. Hasapis, INTRASOFT International S.A., Luxembourg, LU;
  • R. Sahey, A. Iqbal, National University of Ireland, Galway (NUI, Galway) - Digital Enterprise Research Institute (DERI), Galway, IE;
  • J. Keane, A. Gledson, University of Manchester, UK;
  • N. Forgò, Gottfried Wilhelm Leibniz Universität Hannover, DE;
  • K. Tarabanis, Centre for Research and Technology Hellas, Thessaloniki, GR;
  • C. Pattichis, A. Antoniades, A. Aristodimou, University of Cyprus, CY;
  • C. Potlog, SIVECO Romania S.A., Bucharest, RO;
  • K. Perakis, D. Ntalaperas, T. Bouras, UBITECH, Athens, GR;
  • V. Giotaki, ZEINCRO Hellas S.A., Athens, GR;
  • K Kyriacou, C. Demetriou, The Cyprus Foundation for Muscular Dystrophy Research Cyprus Institute of Neurology and Genetics, Nicosia, CY.


Centre for Psychiatric Epidemiology and Psychopathology
Route de Cery 25
CH -1008 Prilly-Lausanne
Fax +41 21 314 8469
Mrs Lucille Touchais
Monday 8h-12h, Tuesday all day, Wednesday 8h00-12h00, Thursday 8h00-12h00
 Last updated on 02/05/2023 at 11:26